While the reported objective response rates for T-DXd have been consistently higher in patients with HER2 3+ expression than in patients with lower HER2 expression levels across solid tumor types19, T-DXd has clinically meaningful anti-tumor activity in patients with HER2-low and even HER2-ultralow breast and lung cancers18,20,50. This evidence concerns the gene ERBB2 and neoplasm.